A condition with abnormally elevated level of AMYLASES in the serum. Hyperamylasemia due to PANCREATITIS or other causes may be differentiated by identifying the amylase isoenzymes.
A group of amylolytic enzymes that cleave starch, glycogen, and related alpha-1,4-glucans. (Stedman, 25th ed) EC 3.2.1.-.
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
An enzyme that hydrolyzes 1,6-alpha-glucosidic branch linkages in glycogen, amylopectin, and their beta-limit dextrins. It is distinguished from pullulanase (EC 3.2.1.41) by its inability to attack pullulan and by the feeble action of alpha-limit dextrins. It is distinguished from amylopectin 6-glucanohydrolase (EC 3.2.1.69) by its action on glycogen. With EC 3.2.1.69, it produces the activity called "debranching enzyme". EC 3.2.1.68.
Pathological processes of the PANCREAS.
Fiberoptic endoscopy designed for duodenal observation and cannulation of VATER'S AMPULLA, in order to visualize the pancreatic and biliary duct system by retrograde injection of contrast media. Endoscopic (Vater) papillotomy (SPHINCTEROTOMY, ENDOSCOPIC) may be performed during this procedure.
Endoscopy of the small intestines accomplished while advancing the endoscope into the intestines from the stomach by alternating the inflation of two balloons, one on an innertube of the endoscope and the other on an overtube.
An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. It is produced by glands on the tongue and by the pancreas and initiates the digestion of dietary fats. (From Dorland, 27th ed) EC 3.1.1.3.
A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
Disease having a short and relatively severe course.
Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.
A specific decapeptide obtained from the skin of Hila caerulea, an Australian amphibian. Caerulein is similar in action and composition to CHOLECYSTOKININ. It stimulates gastric, biliary, and pancreatic secretion; and certain smooth muscle. It is used in paralytic ileus and as diagnostic aid in pancreatic malfunction.

Multiple immune disorders in unrecognized celiac disease: a case report. (1/29)

We reported a female patient with unrecognized celiac disease and multiple extra intestinal manifestations, mainly related to a deranged immune function, including macroamilasemia, macrolipasemia, IgA nephropathy, thyroiditis, and anti-b2-glicoprotein-1 antibodies, that disappeared or improved after the implementation of a gluten-free diet.  (+info)

Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. (2/29)

BACKGROUND: Previous studies suggested that somatostatin given before endoscopic retrograde cholangiopancreatography (ERCP) may reduce the incidence of post-ERCP pancreatitis. However, the routine use of somatostatin in all patients undergoing ERCP is not likely to be cost effective. This study evaluated whether intravenous bolus somatostatin given after diagnostic cholangiopancreatography could reduce the incidence of pancreatitis in a group of patients undergoing therapeutic ERCP procedures. METHODS: In a randomised, double blind, controlled trial, the effect of intravenous bolus somatostatin 250 microg given immediately after diagnostic cholangiopancreatography was compared with that of placebo in patients who required endoscopic sphincterotomy or other therapeutic procedures. The primary end point was the incidence of post-ERCP clinical pancreatitis, and a secondary end point was the incidence of hyperamylasemia. RESULTS: A total of 270 patients were randomised. The somatostatin group (n=135) and the placebo group (n=135) were comparable in age, sex, indications for treatment, and types of procedure. The frequencies of clinical pancreatitis (4.4% v 13.3%; p=0.010) and hyperamylasemia (26.0% v 38.5%; p=0.036) were both significantly lower in the somatostatin group compared with the placebo group. CONCLUSIONS: A single dose of intravenous bolus somatostatin, given immediately after diagnostic cholangiopancreatography, is effective in reducing the incidence of pancreatitis after therapeutic ERCP. This novel approach of administering prophylactic somatostatin may offer a cost effective prophylaxis for post-ERCP pancreatitis.  (+info)

Pancreatic involvement in fatal human leptospirosis: clinical and histopathological features. (3/29)

Hyperamylasemia has been reported in more than 65% of patients with severe leptospirosis, and the true diagnosis of acute pancreatitis is complicated by the fact that renal failure can increase serum amylase levels. Based on these data we retrospectively analyzed the clinical and histopathological features of pancreas involvement in 13 cases of fatal human leptospirosis. The most common signs and symptoms presented at admission were fever, chills, vomiting, myalgia, dehydratation, abdominal pain and diarrhea. Trombocytopenia was evident in 11 patients. Mild increased of AST and ALT levels was seen in 9 patients. Hyperamylasemia was recorded in every patient in whom it was measured, with values above 180 IU/L (3 cases). All patients presented acute renal failure and five have been submitted to dialytic treatment. The main cause of death was acute respiratory failure due to pulmonary hemorrhage. Pancreas fragments were collected for histological study and fat necrosis was the criterion used to classify acute pancreatitis. Histological pancreatic findings were edema, mild inflammatory infiltrate of lymphocytes, hemorrhage, congestion, fat necrosis and calcification. All the patients infected with severe form of leptospirosis who develop abdominal pain should raise the suspect of pancreatic involvement.  (+info)

Hyperamylasaemia and acute pancreatitis in paracetamol poisoning. (4/29)

BACKGROUND: Hyperamylasaemia and even acute pancreatitis have been reported in patients with paracetamol poisoning. AIMS: To describe the incidence, clinical characteristics, and prognostic implications of hyperamylasaemia in paracetamol poisoning. PATIENTS: Six hundred and two patients transferred to a specialized unit with severe paracetamol poisoning and 212 unselected patients admitted from the local region. METHODS: Retrospective study based on hospital charts. The optimum threshold of serum amylase to discriminate non-survivors was identified. RESULTS: An elevated serum amylase (>100 U/L) occurred in 28 of the unselected patients (13%), in 218 of the transferred patients (36%), and in 118 of 148 patients (80%) with fulminant hepatic failure. Only 33 cases of paracetamol-associated acute pancreatitis were diagnosed. A threshold serum amylase of 150 U/L to discriminate non-survivors had sensitivity 76%, specificity 85%, positive predictive value 33%, and negative predictive value 97%. In a logistic regression analysis, a serum amylase > 150 U/L was associated with an excess mortality (odds ratio 5.0, 2.6-9.7). CONCLUSIONS: Hyperamylasaemia is frequent in patients with paracetamol poisoning, whereas clinical acute pancreatitis occurs rarely. The incidence of hyperamylasaemia increases with the degree of hepatic dysfunction. A serum amylase exceeding 1.5 times the upper normal limit indicates a poor prognosis.  (+info)

Lipase and pancreatic amylase activities in diagnosis of acute pancreatitis in patients with hyperamylasemia. (5/29)

BACKGROUND: Measurement of total serum amylase (AMY) is the most widely used biochemical test for the diagnosis of acute pancreatitis, but it is commonly considered a nonspecific marker. To improve the biochemical diagnosis of acute pancreatitis, lipase (LIP) and pancreatic amylase (PAMY) have been tested in recent years. The present study was designed to evaluate whether serum LIP and pancreatic PAMY tests could replace total amylase test to improve diagnostic efficiency in the evaluation of acute pancreatitis in patients with hyperamylasemia. METHODS: LIP and PAMY values were determined in serum samples from 92 patients with hyperamylasemia. Reference values for each enzyme were derived from serum samples of 147 healthy subjects. The activities of LIP and PAMY in patients with various diseases were shown directly by the boxplot graph. The diagnostic accuracy of LIP and PAMY was defined as the area under the receiver operating characteristic (ROC) curve. Their sensitivity and specificity in detecting acute pancreatitis at varying cutoff points were shown by the curve, and the best cutoff value for each enzyme was shown by the modified ROC curve. The diagnostic values of LIP, PAMY and LIP+AMY with each upper limit of reference range (ULR) were compared with the corresponding best cutoff values. RESULTS: The references values of LIP and PAMY were 12.2-47.6 U/L and 28-95 U/L, respectively. These values in patients with acute pancreatitis were higher than those patients with other diseases. The areas under the ROC curve (AUC) of LIP and PAMY were 0.799 and 0.792, respectively. With the best diagnostic cutoff point of maximum (sensitivity + specificity)-100%, we obtained values of 97.9 U/L (LIP(97.9)=2.06 X ULR) for LIP and 209 U/L (PAMY(209)=2.20 X ULR) for PAMY. The best cutoff values for LIP, PAMY and LIP+AMY demonstrated the specificity, positive predictive value, and diagnostic efficiency higher than the corresponding ULRs. CONCLUSIONS: Serum LIP and PAMY are specific for the pancreas and might replace total amylase for the diagnosis of acute pancreatitis in hyperamylasemia patients. LIP(97.9) is more efficient than PAMY(209) in the diagnosis of acute pancreatitis. A combined test of both enzymes is not superior to single test of either enzyme in diagnostic accuracy.  (+info)

Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. (6/29)

The objective of the present study was to determine the efficacy of prophylactic administration of gabexate for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, hyperamylasemia and pancreatic pain. Patients scheduled for ERCP were randomized into two groups in a double-blind manner: the patients in the gabexate group were treated with continuous intravenous infusion of 300 mg gabexate dissolved in 500 mL Ringer's solution at 111 mL/h, starting 30 min before the endoscopic maneuvers and continuing up to 4 h after them; placebo group patients were treated only with Ringer's solution also starting 30 min before the endoscopic maneuvers and continuing up to 4 h. Data for 193 patients were analyzed. The incidence of post-ERCP pancreatitis was 3 patients (3.1%) in the gabexate group and 10 (10.5%) in the placebo group (P = 0.040). The incidence of hyperamylasemia was 33 patients (33.7%) in the gabexate group and 42 (43.7%) in the placebo group (P = 0.133). The incidence of pancreatic pain was 15 patients (15.3%) in the gabexate group and 28 (29.5%) in the placebo group (P = 0.018). The results suggest that a 4.5-h infusion of gabexate (for a total of 300 mg) could prevent post-ERCP pancreatitis and pancreatic pain.  (+info)

N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. (7/29)

AIM: Acute pancreatitis (AP) is the most common and often severe complication of endoscopic retrograde cholangiopancreatography (ERCP). The early step in the pathogenesis of acute pancreatitis is probably the capillary endothelial injury mediated by oxygen-derived free radicals. N-acetylcysteine - a free radical scavenger may be potentially effective in preventing post-ERCP acute pancreatitis and it is also known that N-acetylcysteine (ACC) can reduce the severity of disease in experimental model of AP. METHODS: One hundred and six patients were randomly allocated to two groups. Fifty-five patients were given N-acetylcysteine (two 600 mg doses orally 24 and 12 h before ERCP and 600 mg was given iv, twice a day for two days after the ERCP). The control group consisted of 51 patients who were given iv. isotonic saline twice a day for two days after the ERCP. Serum and urine amylase activities were measured before ERCP and 8 and 24 h after the procedure. The primary outcome parameter was post-ERCP acute pancreatitis and the secondary outcome parameters were differences between groups in serum and urine amylase activity. RESULTS: There were no significant differences in the rate of post-ERCP pancreatitis between two groups (10 patients overall, 4 in the ACC group and 6 in the control group). There were also no significant differences in baseline and post-ERCP serum and urine amylase activity between ACC group and control group. CONCLUSION: N-acetylcysteine fails to demonstrate any significant preventive effect on post-ERCP pancreatitis, as well as on serum and urine amylase activity.  (+info)

Simultaneous complication of multiple myeloma with Sjogren syndrome. (8/29)

We report a 72-year-old female case of IgG-kappa type multiple myeloma (MM) simultaneously complicated with Sjogren syndrome (SS). She also presented marked hyperamylasemia of salivary-type isozyme. Although she had received sequential chemotherapy completed with high-dose therapy with autologous hematopoietic stem cell transplantation, she died of relapse fifteen months after the initial diagnosis. Various autoantibodies indicated that her sicca symptoms were due to true SS and not caused by MM cell infiltration to exocrine glands. MM cells appeared to produce amylase that fluctuated correspondingly to the disease status of MM. To our knowledge, this is the first English report of simultaneous complication of SS and MM referring to hyperamylasemia. Accumulation of this rare clinical manifestation is important to elucidate the pathogenesis of MM under condition of immunological disorder caused by SS.  (+info)

Hyperamylasemia is a medical condition characterized by an elevated level of amylase in the blood. Amylase is an enzyme that is primarily produced by the pancreas and salivary glands, and it plays a crucial role in digesting carbohydrates.

Normally, the levels of amylase in the blood are relatively low, but when there is damage to the pancreas or salivary glands, such as in cases of pancreatitis, salivary gland inflammation, or blockage, the levels of amylase can rise significantly. This condition is called hyperamylasemia.

Mild elevations in amylase levels may not cause any symptoms and may be discovered only during routine blood tests. However, more significant elevations can indicate a serious underlying medical condition that requires prompt treatment. Symptoms of hyperamylasemia may include abdominal pain, nausea, vomiting, fever, and rapid heartbeat.

It is important to note that hyperamylasemia can also be caused by non-pancreatic conditions such as macroamylasemia, a benign condition where large amylase-containing protein complexes are formed and circulate in the bloodstream, leading to elevated amylase levels. Therefore, it is essential to perform further diagnostic tests to determine the underlying cause of hyperamylasemia.

Amylases are enzymes that break down complex carbohydrates, such as starch and glycogen, into simpler sugars like maltose, glucose, and maltotriose. There are several types of amylases found in various organisms, including humans.

In humans, amylases are produced by the pancreas and salivary glands. Pancreatic amylase is released into the small intestine where it helps to digest dietary carbohydrates. Salivary amylase, also known as alpha-amylase, is secreted into the mouth and begins breaking down starches in food during chewing.

Deficiency or absence of amylases can lead to difficulties in digesting carbohydrates and may cause symptoms such as bloating, diarrhea, and abdominal pain. Elevated levels of amylase in the blood may indicate conditions such as pancreatitis, pancreatic cancer, or other disorders affecting the pancreas.

Pancreatitis is a medical condition characterized by inflammation of the pancreas, a gland located in the abdomen that plays a crucial role in digestion and regulating blood sugar levels. The inflammation can be acute (sudden and severe) or chronic (persistent and recurring), and it can lead to various complications if left untreated.

Acute pancreatitis often results from gallstones or excessive alcohol consumption, while chronic pancreatitis may be caused by long-term alcohol abuse, genetic factors, autoimmune conditions, or metabolic disorders like high triglyceride levels. Symptoms of acute pancreatitis include severe abdominal pain, nausea, vomiting, fever, and increased heart rate, while chronic pancreatitis may present with ongoing abdominal pain, weight loss, diarrhea, and malabsorption issues due to impaired digestive enzyme production. Treatment typically involves supportive care, such as intravenous fluids, pain management, and addressing the underlying cause. In severe cases, hospitalization and surgery may be necessary.

Isoamylase is not a medical term per se, but rather a biochemical term used to describe an enzyme. Medically, it may be relevant in the context of certain medical conditions or treatments that involve carbohydrate metabolism. Here's a general definition:

Isoamylase (EC 3.2.1.68) is a type of amylase, a group of enzymes that break down complex carbohydrates, specifically starch and glycogen, into simpler sugars. Isoamylase is more precisely defined as an enzyme that hydrolyzes (breaks down) alpha-1,6 glucosidic bonds in isomaltose, panose, and dextrins, yielding mainly isomaltose and limit dextrin. It is found in various organisms, including bacteria, fungi, and plants. In humans, isoamylase is involved in the digestion of starch in the small intestine, where it helps convert complex carbohydrates into glucose for energy absorption.

Pancreatic diseases refer to a group of medical conditions that affect the structure and function of the pancreas, a vital organ located in the abdomen. The pancreas has two main functions: an exocrine function, which involves the production of digestive enzymes that help break down food in the small intestine, and an endocrine function, which involves the production of hormones such as insulin and glucagon that regulate blood sugar levels.

Pancreatic diseases can be broadly classified into two categories: inflammatory and non-inflammatory. Inflammatory pancreatic diseases include conditions such as acute pancreatitis, which is characterized by sudden inflammation of the pancreas, and chronic pancreatitis, which is a long-term inflammation that can lead to scarring and loss of function.

Non-inflammatory pancreatic diseases include conditions such as pancreatic cancer, which is a malignant tumor that can arise from the cells of the pancreas, and benign tumors such as cysts or adenomas. Other non-inflammatory conditions include pancreatic insufficiency, which can occur when the pancreas does not produce enough digestive enzymes, and diabetes mellitus, which can result from impaired insulin production or action.

Overall, pancreatic diseases can have serious consequences on a person's health and quality of life, and early diagnosis and treatment are essential for optimal outcomes.

Endoscopic retrograde cholangiopancreatography (ERCP) is a medical procedure that combines upper gastrointestinal (GI) endoscopy and fluoroscopy to diagnose and treat certain problems of the bile ducts and pancreas.

During ERCP, a flexible endoscope (a long, thin, lighted tube with a camera on the end) is passed through the patient's mouth and throat, then through the stomach and into the first part of the small intestine (duodenum). A narrow plastic tube (catheter) is then inserted through the endoscope and into the bile ducts and/or pancreatic duct. Contrast dye is injected through the catheter, and X-rays are taken to visualize the ducts.

ERCP can be used to diagnose a variety of conditions affecting the bile ducts and pancreas, including gallstones, tumors, strictures (narrowing of the ducts), and chronic pancreatitis. It can also be used to treat certain conditions, such as removing gallstones from the bile duct or placing stents to keep the ducts open in cases of stricture.

ERCP is an invasive procedure that carries a risk of complications, including pancreatitis, infection, bleeding, and perforation (a tear in the lining of the GI tract). It should only be performed by experienced medical professionals in a hospital setting.

Double-balloon enteroscopy (DBE) is a medical procedure used to examine the small intestine, which is difficult to reach with traditional endoscopes due to its length and twists and turns. DBE uses a specialized endoscope with two inflatable balloons on its tip. The endoscope is inserted through the mouth or the rectum and advanced slowly into the small intestine while alternately inflating and deflating the balloons to help move the endoscope forward and provide better visualization of the intestinal lining.

DBE can be used for diagnostic purposes, such as evaluating obscure gastrointestinal bleeding, Crohn's disease, tumors, or polyps in the small intestine. It can also be used for therapeutic interventions, such as removing polyps, taking biopsies, or placing feeding tubes.

The procedure is usually done under sedation and takes several hours to complete. While it is considered a safe procedure, potential risks include perforation of the intestinal wall, bleeding, and adverse reactions to the anesthesia.

Lipase is an enzyme that is produced by the pancreas and found in the digestive system of most organisms. Its primary function is to catalyze the hydrolysis of fats (triglycerides) into smaller molecules, such as fatty acids and glycerol, which can then be absorbed by the intestines and utilized for energy or stored for later use.

In medical terms, lipase levels in the blood are often measured to diagnose or monitor conditions that affect the pancreas, such as pancreatitis (inflammation of the pancreas), pancreatic cancer, or cystic fibrosis. Elevated lipase levels may indicate damage to the pancreas and its ability to produce digestive enzymes.

The pancreas is a glandular organ located in the abdomen, posterior to the stomach. It has both exocrine and endocrine functions. The exocrine portion of the pancreas consists of acinar cells that produce and secrete digestive enzymes into the duodenum via the pancreatic duct. These enzymes help in the breakdown of proteins, carbohydrates, and fats in food.

The endocrine portion of the pancreas consists of clusters of cells called islets of Langerhans, which include alpha, beta, delta, and F cells. These cells produce and secrete hormones directly into the bloodstream, including insulin, glucagon, somatostatin, and pancreatic polypeptide. Insulin and glucagon are critical regulators of blood sugar levels, with insulin promoting glucose uptake and storage in tissues and glucagon stimulating glycogenolysis and gluconeogenesis to raise blood glucose when it is low.

An acute disease is a medical condition that has a rapid onset, develops quickly, and tends to be short in duration. Acute diseases can range from minor illnesses such as a common cold or flu, to more severe conditions such as pneumonia, meningitis, or a heart attack. These types of diseases often have clear symptoms that are easy to identify, and they may require immediate medical attention or treatment.

Acute diseases are typically caused by an external agent or factor, such as a bacterial or viral infection, a toxin, or an injury. They can also be the result of a sudden worsening of an existing chronic condition. In general, acute diseases are distinct from chronic diseases, which are long-term medical conditions that develop slowly over time and may require ongoing management and treatment.

Examples of acute diseases include:

* Acute bronchitis: a sudden inflammation of the airways in the lungs, often caused by a viral infection.
* Appendicitis: an inflammation of the appendix that can cause severe pain and requires surgical removal.
* Gastroenteritis: an inflammation of the stomach and intestines, often caused by a viral or bacterial infection.
* Migraine headaches: intense headaches that can last for hours or days, and are often accompanied by nausea, vomiting, and sensitivity to light and sound.
* Myocardial infarction (heart attack): a sudden blockage of blood flow to the heart muscle, often caused by a buildup of plaque in the coronary arteries.
* Pneumonia: an infection of the lungs that can cause coughing, chest pain, and difficulty breathing.
* Sinusitis: an inflammation of the sinuses, often caused by a viral or bacterial infection.

It's important to note that while some acute diseases may resolve on their own with rest and supportive care, others may require medical intervention or treatment to prevent complications and promote recovery. If you are experiencing symptoms of an acute disease, it is always best to seek medical attention to ensure proper diagnosis and treatment.

The pancreatic ducts are a set of tubular structures within the pancreas that play a crucial role in the digestive system. The main pancreatic duct, also known as the duct of Wirsung, is responsible for transporting pancreatic enzymes and bicarbonate-rich fluid from the pancreas to the duodenum, which is the first part of the small intestine.

The exocrine portion of the pancreas contains numerous smaller ducts called interlobular ducts and intralobular ducts that merge and ultimately join the main pancreatic duct. This system ensures that the digestive enzymes and fluids produced by the pancreas are effectively delivered to the small intestine, where they aid in the breakdown and absorption of nutrients from food.

In addition to the main pancreatic duct, there is an accessory pancreatic duct, also known as Santorini's duct, which can sometimes join the common bile duct before emptying into the duodenum through a shared opening called the ampulla of Vater. However, in most individuals, the accessory pancreatic duct usually drains into the main pancreatic duct before entering the duodenum.

Ceruletide is a synthetic analog of the natural hormone cholecystokinin (CCK). It is a decapeptide with the following sequence: cyclo(D-Asp-Tic-Phe-Ser-Leu-Hand-Ala-Lys-Thr-Nle-NH2).

Ceruletide has several pharmacological actions, including stimulation of the release of digestive enzymes from the pancreas, contraction of the gallbladder and sphincter of Oddi, and inhibition of gastric acid secretion. It is used in clinical medicine for diagnostic purposes to test the motor function of the biliary tract and to diagnose gastrointestinal motility disorders.

Ceruletide has also been investigated as a potential treatment for certain conditions such as pancreatitis, gallstones, and intestinal obstruction, but its use is limited due to its side effects, which include nausea, vomiting, abdominal cramps, and diarrhea.

"Diagnosing macroamylaemia in unexplained hyperamylasemia". Acta Med Croatica. 71: 63-67. Kleinman, David S.; O'Brien, John F. ( ...
Ben-Horin, S., Farfel Z., Mouallem, M. (2002), "Gastroenteritis-associated hyperamylasemia: Prevalence and clinical ...
... lowers post-ERCP hyperamylasemia but not pancreatitis incidence". Gastrointestinal Endoscopy. 68 (2): 246-54. doi:10.1016/j.gie ... although investigators observed a significant reduction of the incidence of hyperamylasemia and the levels of post-ERCP amylase ...
Many conditions have been reported to cause hyperamylasemia. Although hyperamylasemia is commonly assumed to be due to the ... encoded search term (Hyperamylasemia) and Hyperamylasemia What to Read Next on Medscape ... Hyperamylasemia in diabetic ketoacidosis: sources and significance. Ann Intern Med. 1979 Aug. 91(2):200-4. [QxMD MEDLINE Link] ... Other reasons for hyperamylasemia that are associated with pancreatitis are pseudocysts, pancreatic ascites, pancreatic trauma, ...
Hyperamylasemia is a serum amylase level above the upper limit of normal (range, 30-110 U/L). An elevated serum amylase is ... It usually causes hyperamylasemia with an ACCR of ,1% [5]. The prevalence of macroamylasemia is around 1% in the general ... 3. Tseng Y, Luo Z, Zhang H, Zhang C, Chen J. Asymptomatic hyperamylasemia in Stevens-Johnson syndrome is associated with ... 7. Joksimovic Z, Bastac D, Pavlovic S. Macroamylasemia as a cause of hyperamylasemia in clinically unclear conditions: case ...
"Diagnosing macroamylaemia in unexplained hyperamylasemia". Acta Med Croatica. 71: 63-67. Kleinman, David S.; OBrien, John F. ( ...
Hyperamylasemia (,2.0 x ULN). 5 (2%). 1 (,1%). Hyperglycemia (,13.9 mmol/L). 2 (,1%). 2 (,1%). ...
Hyperamylasemia (,2.0 x ULN). 5 (2%). 1 (,1%). Hyperglycemia (,13.9 mmol/L). 2 (,1%). 2 (,1%). ...
Result of the blood analysis indicated hyperamylasemia. The abdominal computed tomography (CT) scan showed diffuse parenchymal ...
Hyperamylasemia Hyperplasia + hyperuricemia + Hypovolemia immune system disease + Inflammation + A pathological process ...
Risk of hyperamylasemia and acute pancreatitis after double-balloon enteroscopy: a prospective study. Endoscopy. 2011;43(9):766 ... Liu Z, Wang J, Qian J, Tang F. Hyperamylasemia, reactive plasmacytosis, and immune abnormalities in a patient with celiac ... Pancreatic hyperamylasemia and hyperlipasemia in association with cytomegalovirus infection following unrelated cord blood ... Hyperamylasemia and pancreatitis following spiral enteroscopy. Can J Gastroenterol. 2012;26(9):603-6. ...
Hyperamylasemia. 3. 1. Inflammation. 3. 2. Insulin Disorders. 3. 2. Kidney Stones. 3. 1. ...
Hyperamylasemia with prolonged ileus has been encountered in several patients who responded favorably to medical management. A ...
Hyperamylasemia is often observed.  Cardiotoxicity: acetaminophen - induced cardiotoxicity is rarely clinically significant, ...
hyperamylasemia may be an associated finding. Clinical presentation. Non-specific symptoms such as pain caused by local mass ...
N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. ...
Hyper-amylasemia is seen at each of these episodes, which is generally considered to be caused by acute pancreatitis. However, ... In groups III and IV, hyper-amylasemia were proven in 60 to 120 minutes after the start of infusion with a statistical ... according to our observations in clinical and experimental studies to date, hyper-amylasemia is supposed to be related to ...
Postoperative hyperamylasemia (POH) and acute pancreatitis after pancreatoduodenectomy (POAP): state of the art and systematic ... Hyperamylasemia and acute pancreatitis after pancreatoduodenectomy: two different entities. Surgery. 2021;169(2):369-76. ...
... hyperamylasemia, hypocholesterolemia, and moderately high alkaline phosphatase, aspartate transaminase, and creatine kinase ...
Hyperamylasemia During Omalizumab Therapy Esra KARABİBER, Özge ÖZTÜRK AKTAŞ, Ebru ÖZDEMIR, Ebru DAMADOĞLU, Ümit Murat ŞAHINER, ...
O Hyperamylasemia,O Hyperapobetalipoproteinemia,O Hyperargininemia,O Hyperasparaginemia,O Hyperautofluorescent macular lesion,O ...
hyperamylasemia / Delayed / 0-20.0. hyponatremia / Delayed / 0-15.0. hypertension / Early / 0-15.0. hypercalcemia / Delayed / 0 ...
... hyperamylasemia), visual impairment, low blood sugar (hypoglycemia), and diarrhea. Pretomanid used in combination with ...
hyperamylasemia / Delayed / 0-10.0. thrombocytopenia / Delayed / 0-10.0. lymphocytosis / Delayed / 0-10.0. eosinophilia / ...
Two patients are described who developed acute abdominal pain, marked hyperamylasemia, and palpable abdominal masses 5 and 15 ... Two patients are described who developed acute abdominal pain, marked hyperamylasemia, and palpable abdominal masses 5 and 15 ... Two patients are described who developed acute abdominal pain, marked hyperamylasemia, and palpable abdominal masses 5 and 15 ... Two patients are described who developed acute abdominal pain, marked hyperamylasemia, and palpable abdominal masses 5 and 15 ...
Hyperamylasemia (> 2 x ULN). 5 (2%). 1 (< 1%). Hyperglycemia (> 13.9 mmol/L) ...
A knowledge graph of biological entities such as genes, gene functions, diseases, phenotypes and chemicals. Embeddings are generated with Walking RDF and OWL method ...
Hi, I have red prominent veins in the left of my eye. Dr said its neovascularisation. I havent ... there? Is there nothing to remove them? Thanks!
Hyperamylasemia common. ¤ Abnormal aminotransferases, hyperbilirubinemia, mild increase in serum alkaline phosphatase more ...
What is hyperamylasemia? How many boys live in the US with Duchenne Muscular Dystrophy today? Different types of gem fractures? ...
  • Although hyperamylasemia is commonly assumed to be due to the release of amylase into the serum by the diseased organ, the precise relationship between hyperamylasemia and an affecting condition is not entirely clear. (medscape.com)
  • Hyperamylasemia is most commonly the result of (1) pancreatitis or parotitis , (2) decreased metabolic clearance of amylase, or (3) amylase released from an involved organ. (medscape.com)
  • Hyperamylasemia is a serum amylase level above the upper limit of normal (range, 30-110 U/L). An elevated serum amylase is observed in around 75% of cases of pancreatitis. (kjfm.or.kr)
  • The other eight dogs receiving iv bolus doses of anticholinesterase in addition to Secretin developed acute hyperamylasemia and hyperlipasemia. (cdc.gov)
  • Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. (ijmb.in)
  • However, there are several other conditions that can cause hyperamylasemia or hyperlipasemia, such as gut perforation and renal failure. (corporatetaxratenow.com)
  • Donor age, mechanism of death, medical history, and perimortem hyperglycemia or hyperamylasemia affect suitability of the pancreatic graft. (mhmedical.com)
  • Two patients are described who developed acute abdominal pain, marked hyperamylasemia, and palpable abdominal masses 5 and 15 years after Billroth II gastrectomy. (psu.edu)
  • A history of previous gastrectomy, recurrent or severe abdominal pain, hyperamylasemia with characteristic tomography, and endoscopic findings will establish the diagnosis and necessitate surgical evaluation and intervention. (psu.edu)
  • A definite association implies a temporal relationship of drug administration to abdominal pain and hyperamylasemia or to a positive response to rechallenge. (pocketdrugguide.com)
  • Prolonged hyperamylasemia in patients experiencing a first attack of acute pancreatitis is associated with recurrence of acute pancreatitis. (medscape.com)
  • The smart year book 2017 of the German Information Center forClonidine transiently reverses acute hyperamylasemia due to serum sickness. (steppingstonesmalta.com)
  • [ 2 ] Patients with pancreatitis associated with hypertriglyceridemia or those with considerable acinar cell injury due to previous episodes of pancreatitis or chronic pancreatitis may not exhibit hyperamylasemia. (medscape.com)
  • We describe two patients in whom clonidine 0.2 mg IV decreased hyperamylasemia. (steppingstonesmalta.com)
  • Result of the blood analysis indicated hyperamylasemia. (hindawi.com)
  • High-dose Intravenous Glucocorticoid Induces Hyperamylasemia These four patients developed hyperamylasemia following high-dose intravenous glucocorticoid. (medscape.com)
  • TODOROV, R. Immunological Pathways in the Development of Postoperative Hyperamylasemia and Postoperative Pancreatitis - Preliminary Results. (bas.bg)
  • Hyperamylasemia following the trans-sphenoidal resection of pituitary tumor: can propofol-remifentanil TIVA cause postoperative hyperamylasemia? (anesth-pain-med.org)
  • Although hyperamylasemia is commonly assumed to be due to the release of amylase into the serum by the diseased organ, the precise relationship between hyperamylasemia and an affecting condition is not entirely clear. (medscape.com)
  • Hyperamylasemia is most commonly the result of (1) pancreatitis or parotitis , (2) decreased metabolic clearance of amylase, or (3) amylase released from an involved organ. (medscape.com)
  • Variables such as thrombocytopenia, hyperneutrophilia, hyperamylasemia, and elevated asparate aminotransferase levels are laboratory findings of severe leptospirosis (and not risk factors of disease). (cdc.gov)
  • Etiological differentiation of hyperamylasemia should be emphasized in clinical practice, especially when the diagnosis of acute pancreatitis is not clear. (medscape.com)
  • Prolonged hyperamylasemia in patients experiencing a first attack of acute pancreatitis is associated with recurrence of acute pancreatitis. (medscape.com)
  • [ 2 ] Patients with pancreatitis associated with hypertriglyceridemia or those with considerable acinar cell injury due to previous episodes of pancreatitis or chronic pancreatitis may not exhibit hyperamylasemia. (medscape.com)
  • 16. Carcinoma of the lung with marked hyperamylasemia and elevated serum calcitonin. (nih.gov)
  • Including laboratory findings such as thrombocytopenia, hyperneutrophilia, and hyperamylasemia in the model was appropriate for the following reasons. (cdc.gov)
  • 8. Marked hyperamylasemia associated with carcinoma of the lung. (nih.gov)
  • 9. Hyperamylasemia with carcinoma of the lung. (nih.gov)
  • [8] [9] In a group of 74 patients with surgically resectable lung cancer,13 showed hyperamylasemia. (statpearls.com)
  • Glucocorticoids have many side effects, and high-dose intravenous application may cause rare adverse reactions such as hyperamylasemia. (medscape.com)
  • In all, 51 (32%) subjects had hyperamylasemia, 9 (6%) hyperlipasemia, and 100 (62%) an increase in both enzyme levels. (univr.it)
  • Results: Administration of caerulein produced hyperamylasemia and morphologic changes of the pancreas including interstitial edema, acinar cell vacuolization, and infiltration of inflammatory cells. (elsevierpure.com)